(Q46857131)

25 December 2017

title

The safety profiles of orlistat and sibutramine: results of prescription-event monitoring studies in England (English)

1 reference

25 December 2017

1 reference

Michael J Perrio

1

1 reference

25 December 2017

Lynda V Wilton

series ordinal

2

1 reference

25 December 2017

Saad A W Shakir

series ordinal

3

1 reference

25 December 2017

publication date

1 November 2007

1 reference

25 December 2017

published in

Obesity

1 reference

25 December 2017

volume

15

1 reference

25 December 2017

issue

11

1 reference

25 December 2017

page(s)

2712-2722

1 reference

25 December 2017

Sibutramine use associated with reversible hepatotoxicity

cites work

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.323

Underreporting of suspected adverse drug reactions to newly marketed ("black triangle") drugs in general practice: observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.323

Meta-analysis: pharmacologic treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.323

Hypothyroidism in thyroid carcinoma follow-up: orlistat may inhibit the absorption of thyroxine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.323

Obesity in transplant patients: case report showing interference of orlistat with absorption of cyclosporine and review of literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.323

In defense of case reports and case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.323

Orlistat: a review of its use in the management of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.323

Sibutramine. A review of its contribution to the management of obesity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.323

Perspectives on the use of data mining in pharmaco-vigilance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.323

Detection, verification, and quantification of adverse drug reactions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.323

Case reports of suspected adverse drug reactions--systematic literature survey of follow-up

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.323

Case reports of suspected adverse drug reactions: case reports were dismissed too quickly

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.323

Case reports of suspected adverse drug reactions: case reports generate signals efficiently

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.323

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.323

Safety of drug therapies used for weight loss and treatment of obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.323

Safety profile of orlistat: results of a prescription-event monitoring study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.323

Orlistat associated subacute hepatic failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.323

Massive hepatocellular [correction of hepatocullular] necrosis: was it caused by Orlistat?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.323

Orlistat associated with hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.323

Interaction between orlistat and antihypertensive drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.323

Constipation, polyuria, polydipsia, and edema associated with orlistat

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.323

Lichenoid eruption associated with orlistat

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.323

Organic hypomania secondary to sibutramine-citalopram interaction.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.323

Sibutramine and panic attacks

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.323

Sibutramine-associated psychotic episode

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.323

QT interval prolongation associated with sibutramine treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.323

Severe bullous drug eruption due to sibutramine (Reductil).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.323

Prescription-event monitoring and reporting of adverse drug reactions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.323

A systematic review of the clinical effectiveness of orlistat used for the management of obesity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.323

Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.323

Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.323

Reduction of body weight and co-morbidities by orlistat: The XXL--Primary Health Care Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.323

Orlistat associated with hypertension. Digit preference lays conclusions about orlistat open to doubt

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.323

Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.323

Obesity: weighing the risk before prescribing

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.323

Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.323

Diabetic ketoacidosis associated with orlistat treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.323

Orlistat-induced cutaneous leukocytoclastic vasculitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.323

Orlistat enhances warfarin effect

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.323

Case study: metformin-associated lactic acidosis: could orlistat be relevant?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.323

Additive gastrointestinal effects with concomitant use of olestra and orlistat

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.323

Drug interaction in a renal transplant patient: cyclosporin-Neoral and orlistat

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.323

Reduction in blood cyclosporine concentration by orlistat in two renal transplant patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.323

Effect of orlistat on blood cyclosporin concentration in an obese heart transplant patient

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.323

Co-administration of orlistat and cyclosporine in a heart transplant recipient

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.323

Orlistat decreases the plasma level of cyclosporine and may be responsible for the development of acute rejection episodes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.323

The effect of managed care on medical education

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.323

Are mood disorders and obesity related? A review for the mental health professional.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.323

Sibutramine: possible cause of a reversible cardiomyopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.323

Interaction between sibutramine and cyclosporine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.323

Validity of anecdotal reports of suspected adverse drug reactions: the problem of false alarms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.323

Case reports and drug safety

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2007.323

31 March 2020

Identifiers

DOI

10.1038/OBY.2007.323

1 reference

25 December 2017

1 reference

25 December 2017